66 results about "Lipocalin" patented technology

The invention discloses a latex-enhanced immunoturbidimetric assay kit for neutropil gelatinase-associated lipocalin, and a preparation method thereof. Polyethylene glycol hexamine is selected as theblocking agent of an antibody binding latex particle. The kit used for latex-enhanced immunoturbidimetric assay of the NGAL has the advantages of high detection specificity, high sensitivity and goodstability, and can efficiently detect the NGAL content in urine, plasma and serum, and the detection result is well associated with fluorescence immunochromatography and enzyme linked immunosorbent assay.

The invention provides antibodies reactive with distinct lipocalin epitopes that are useful for detecting inflammation and bacterial infections in mammals.

The invention relates to a method for diagnosing, evaluating or testing a cancer and foreseeing the severity of the cancer. The testing method comprises the following steps: an antibody of anti-human tropic neutrophil gelatinase-associated lipocalin (NGAL) is reacted with the human NGAL of a specimen to be tested to form a compound which causes turbidity change; light protection intensity or light scattering intensity is used for presenting the change; the human NGAL content of the specimen to be tested is tested through a standard curve of the concentration of human NGAL standard to relevant light protection intensity or light scattering intensity; and finally the cancer severity is measured based on the tested NGAL content. The method has the advantages of high flexibility, high recovery and good repetitiveness, determines a testing method with great convenience, good repetitiveness and strong suitability for the NGAL in urine or blood plasma of a cancer patient, and provides possibility for the clinical directive function of human NGAL and further research of the functions of the human NGAL.

A method of assessing the ongoing kidney status of a mammal afflicted with or at risk of developing chronic renal injury or disease, including chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in urine, serum or plasma samples at discrete time periods, as well as over time. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening chronic renal disease or CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF.

The invention relates to an immunonephelometry kit for detecting lipid carrier protein related to neutrophils gelatinase and a preparation method thereof; an application liquid bottle, an antibody suspending liquid bottle and a standard substance bottle are placed in a box body; application liquid is arranged in the application liquid bottle, and comprises the following components of: 0.01 percent to 1 percent of surfactant, 0.01 percent to 0.5 percent of preservative, 1 percent to 20 percent of sodium chloride and 20mmol/l to 200mmol/l of buffer solution; the antibody suspending liquid bottle contains emulsion suspension which is coated with the monoclonal antibody of the lipid carrier protein related to the neutrophils gelatinase, and the emulsion suspension has the following components of: 0.05 percent to 0.5 percent of emulsion which is coated with the monoclonal antibody of the lipid carrier protein related to the neutrophils gelatinase, 0.01 percent to 1 percent of surfactant, 0.01 percent to 0.5 percent of preservative and 20mmol/l to 200mmol/l of buffer solution; and the standard substance bottle contains the standard substances of the lipid carrier protein related to the neutrophils gelatinase. According to the invention, the mass quantitative detection on a biochemical instrument is realized.

The invention discloses a hybridoma cell strain 3B1 and a hybridoma cell strain 4C2 and a mouse anti-human NGAL monoclonal antibody 3B1 and a mouse anti-human NGAL monoclonal antibody4C2 produced respectively. The two kinds of monoclonal antibodies belong to a same immunoglobulin G (IgG) 2a subclass, but identify various epitopes and can perform specific binding to NGAL recombinant protein with amino acid sequences represented by SEQ ID NO.1. The two monoclonal antibodies can be applied to detect the concentration of the NGAL in human body fluids and have significant application prospect.

The present invention discloses a serum-free and heterologous component-free mesenchymal stem cell culture medium and an application thereof, and firstly discloses the mesenchymal stem cell culture medium. The mesenchymal stem cell culture medium comprises a basal culture medium and a supplement, the basal culture medium is a DMEM/F12 culture medium, and the supplement is a human platelet lysate and/or human lipocalin 2. The present invention further discloses the application of the mesenchymal stem cell culture medium in culturing mesenchymal stem cells. The provided mesenchymal stem cell culture medium is free of serum and heterologous components, ensures safety of clinical application, is simple in components, good in batch-to-batch stability and strong in cell expansion ability in vitro, meets industrial transformation requirements, can well maintain immune regulation ability and multi-directional differentiation ability of the mesenchymal stem cells, and ensures effective functions in clinical treatment.

The invention provides a detection kit for neutrophil gelatinase-associated lipocalin, which is characterized in that it includes reagent 1 and reagent 2; the reagent 1 includes: 10-100 mmol/L buffer, 0.1 -1% w/v of turbidity agent, 0.01-0.05% w/v of preservative; said reagent 2 includes: 0.1-0.5% w/v labeled with anti-human neutrophil gelatinase-associated lipocalin sensitizing latex particles, 0.1-5% w/v stabilizer, 10-100 mmol/L buffer, 0.01-0.05% w/v preservative. The latex particles include latex particles of two different particle sizes, and the latex particles of the two particle sizes are mixed in an appropriate ratio. The kit has high sensitivity, wide linear range and good precision, and is suitable for automatic biochemical analyzers.

An early-stage screening kit for diabetic nephropathy is disclosed. The kit comprises detection agents. The detection agents comprise a first detection agent, a second detection agent, a third detection agent and a fourth detection agent. The solute of the first detection agent is a first podocalyxin antibody. The solute of the second detection agent is a first IV type collagen antibody. The solute of the third detection agent is a first liver-type fatty acid-binding protein antibody. The solute of the fourth detection agent is a first neutrophils gelatinase-associated lipocalin antibody. The kit adopts podocalyxin, IV type collagen, liver-type fatty acid-binding protein and neutrophils gelatinase-associated lipocalin as biomarkers, and can provide assisted determination for renal injury according to actual detection results, thus providing assistance for differentiating early-stage diabetic nephropathy.

An early-stage detection kit for diabetic nephropathy is disclosed. The kit comprises detection agents. The detection agents comprise two or three of a first detection agent, a second detection agent, a third detection agent and a fourth detection agent. The solute of the first detection agent is a first podocalyxin antibody. The solute of the second detection agent is a first IV type collagen antibody. The solute of the third detection agent is a first liver-type fatty acid-binding protein antibody. The solute of the fourth detection agent is a first neutrophils gelatinase-associated lipocalin antibody. The kit adopts two or three of podocalyxin, IV type collagen, liver-type fatty acid-binding protein and neutrophils gelatinase-associated lipocalin as biomarkers, and can provide assisted determination for renal injury according to actual detection results, thus providing assistance for differentiating early-stage diabetic nephropathy.

The invention relates to anti-human neutrophil gelatinase-associated lipocalin antibodies and application thereof in a test paper card. A variety of antibodies are prepared and a set of antibody combinations (NG02 and NG19) with sensitivity and specificity that can meet the needs is obtained through paired screening; and at the same time, the antibodies are convenient for mass production and can meet the needs of large-scale clinical application in the future. A colloidal gold immunochromatographic quantitative detection card with simple operation, sensitivity, specificity and related detection performance which can meet human blood or urine sample detection and used for human neutrophil gelatinase-associated lipocalin is obtained by debugging and optimizing a detection system for the above antibody combinations.

Belonging to the field of biotechnologies, the invention relates to a screening method for a paraquat simulation antibody and application thereof. The simulation antibody is screened out from a ribosome display Lipocalin simulation antibody library and is subjected to soluble functional expression. The invention also relates to a method of screening the paraquat simulation antibody by a ribosome display technology. The paraquat simulation antibody screened out in the invention can be used for paraquat residual monitoring and development of a kit for rapid detection of pesticide paraquat residual.

The invention discloses an immunochromatography device for synchronously and quantitatively detecting different molecular forms of human neutrophil lipocalin (HNL) and a preparation method thereof, and belongs to the field of laboratory medicine. The device is composed of sample diluent freeze-dried powder, standard substance freeze-dried powder and an immunochromatography test strip. The immunochromatography test strip is composed of a liner plate, two blood filtration membranes, a sample flow pad, a UCP combination pad, an analysis membrane and an absorption pad. The UCP combination pad is coated with an antibody capable of resisting three molecular forms of HNL with UCP markers; the analysis membrane is provided with three parallel detection regions (T1, T2 and T3) and a quality control region C, and the three detection regions are coated with an antibody capable of resisting a matrix metal protease-9, an antibody capable of resisting a monomer HNL and an antibody capable of resisting homodimer; the quality control region C is coated with an antibody from animal immune globulin with the UCP marker. One sample can detect three molecular forms of HNL in a combined mode on the same test strip, and the device has the advantages of being rapid, quantitative, easy and convenient to use and the like and has the large scientific research and clinic application prospects.

The present invention relates to the means and methods for the detection of bacterial infections, methods discriminating between viral and bacterial infections, methods of stratifying patients for subsequent treatment and further diagnostic purposes and methods to monitor antibiotherapy. The present invention is based on the detection of specific epitopes of human neutrophil lipocalin (HNL) using specific binding agents.

The invention relates to a set of serum markers for detection of aortic aneurysm/aortic dissection and application thereof. The set of serum markers can be individually used for or arbitrarily combined for distinguishing aortic aneurysm/aortic dissection patients and normal people. The serum markers are protein factors, which include: LCN2: lipocalin, SAA: serum amyloid protein A.

The present invention concerns targeting a cell death factor associated with cancer. More specifically, an apoptosis-inducing factor is targeted to prevent destruction of non-cancerous cells. The factor may be a lipocalin molecule, and in specific embodiments its secretion and/or the secreted form is targeted by an inhibitory agent, such as an antibody, small molecule, antisense RNA, or siRNA, for example.

The invention relates to a quantitative detection card of human neutrophil gelatinase-associated lipocalin and clinical application thereof. Several kinds of antibodies are prepared and pairing and screening are carried out; and one group of antibodies including NG02 and NG19 that have the sensitivity and specificity meeting the requirements of the quantitative detection card is obtained. Meanwhile, the large-scale production is realized conveniently and thus the need of large-scale clinical application in future is met. After debugging optimization work of the detection system on the antibodygroup, the quantitative detection card of human neutrophil gelatinase-associated lipocalin is obtained, wherein the quantitative detection card has advantages of simple operation and high sensitivityand has the specificity and related detection performance that can meet the body blood and urine sample detection requirement.

The invention discloses a use of neutrophil gelatinase-associated lipocalin in promoting a therapeutic antibody to cross a blood-brain barrier. The therapeutic antibody is a nanocapsule containing immune globulin. The neutrophil gelatinase-associated lipocalin enters blood through intravenous injection to play a role in increasing the permeability of a blood-brain barrier. According to the presentinvention, lipoprotein related to neutrophil gelatinase is intravenously injected into blood circulation of a glioma animal model, the permeability of a blood-brain barrier can be improved, and therefore the total amount of therapeutic antibodies crossing the blood-brain barrier is increased, and particularly, when the therapeutic antibodies select nanocapsules containing immune globulin, the effect that the medicine passes through the blood-brain barrier can be further improved, a better treatment effect is achieved, and extremely high clinical transformation significance is achieved.

The invention relates to a reagent for the quantitative determination of NGAL (Neutrophil Gelatinase-Associated Lipocalin) content in human serum. The reagent comprises a reagent I and a reagent II which are placed separately, wherein the reagent I contains T phosphate buffer and polyethylene glycol-6000; the reagent II contains mouse anti-human NGAL monoclonal antibody latex particles and an antibody stabilizer. A kit and a detection method adopted in the invention only require a few microlitres of serum, need no centrifugation or electrophoresis and other separation treatments, are easy to operate, can meet the requirements of automatic analysis, and are applicable to the timely and accurate detection of large-scale samples.

The invention relates to a biomarker for predicting adverse events in patients with the acute pulmonary embolism, an application thereof, and in particular, an application of lipocalin-2 (LCN-2) for predicting the long-term poor outcomes of the hemodynamically stable acute pulmonary embolism. The long-term poor outcomes refer to all-cause mortality and/or recurrent events of venous thromboembolism. The application relates to: the LCN-2 can independently predict the long-term poor prognosis of the hemodynamically stable acute pulmonary embolism, and meanwhile the risk re-stratification abilityof the long-term poor outcomes of intermediate-risk groups of patients with the acute pulmonary embolism can be improved based on the current risk stratification in combination with the LCN-2 (critical value 11ng/m1).

Methods for determining the risk of developing acute renal failure in a human subject by measuring human neutrophil gelatinase-associated lipocalin (NGAL) are provided.

A method is provided of diagnosing and monitoring acute renal injury leading to acute renal failure in a human or mammalian subject by determining the ratio of the concentration of neutrophil gelatinase-associated lipocalin (NGAL) in urine to that in plasma or serum.